SUBSCRIBE
SUBSCRIBE

Phase 2

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Anavex’s Alzheimer’s Drug a Possible Game Changer After Patients Reported Remarkable Positive Response
April 27, 2016
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
From 20 to 84 Employees in Just Four Years, Booming Blueprint Medicines Maps Out a Plan
April 25, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
Struggling Ariad’s Luck Might be Turning Around as Company Eyes Pfizer’s ALK Space
April 12, 2016
 · 
2 min read
Drug Development
Shift in R&D Strategy Forces BIND Therapeutics to Slash 38% of Workforce, Look for New Capital and Deals
April 6, 2016
 · 
2 min read
Alnylam Stock Craters After Deaths Cause Clinical Trial to End
Drug Development
Alnylam’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry
April 1, 2016
 · 
7 min read
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015
Drug Development
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015
March 23, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Drug Development
Four Biopharma Company Stocks Take Bounces on Good News
March 21, 2016
 · 
3 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Drug Development
TauRx Pharma Co-Founder’s 30-Year Alzheimer’s Quest May Bear Fruit in July
March 18, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Investors Hold Their Breath for Data from Aduro Biotech, Novartis AG
March 11, 2016
 · 
3 min read
Biowarfare Company Emergent's Cancer Spinoff Aptevo Therapeutics to Employ 70 - 90 in Seattle
Drug Development
Embattled Bay Area XOMA Terminates Gevokizumab Trials
March 11, 2016
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
July 10, 2026
 · 
4 min read
Press Releases
LEO Pharma Announces Key Results of Phase 2 TRAPEDS-1 Trial Evaluating Pharmacokinetics and Safety of Tralokinumab in Children With Moderate-to-Severe Atopic Dermatitis
July 9, 2026
 · 
6 min read
Press Releases
Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
July 9, 2026
 · 
4 min read
Press Releases
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
July 9, 2026
 · 
7 min read
Press Releases
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
July 9, 2026
 · 
9 min read
Press Releases
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
July 9, 2026
 · 
7 min read
Press Releases
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
July 9, 2026
 · 
6 min read
Press Releases
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo
July 9, 2026
 · 
3 min read
Press Releases
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial
July 8, 2026
 · 
6 min read
Press Releases
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026
July 8, 2026
 · 
6 min read
Press Releases
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
July 8, 2026
 · 
21 min read
Press Releases
Eradivir Doses First Influenza Patient With EV25 in Bangladesh Study
July 7, 2026
 · 
3 min read
Press Releases
Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 in Idiopathic Parkinson’s Disease
July 7, 2026
 · 
4 min read
Press Releases
FibroBiologics Completes Manufacturing of Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
July 7, 2026
 · 
5 min read
Press Releases
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
July 7, 2026
 · 
4 min read
Press Releases
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
July 7, 2026
 · 
10 min read
Press Releases
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
July 7, 2026
 · 
9 min read
Press Releases
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma
July 7, 2026
 · 
10 min read
Press Releases
CoRegen, Inc. Receives FDA Clearance to Advance CRG-150 into Phase 1/2a Clinical Trials, Pioneering a New Frontier in Cell Therapy for Multiple Solid Tumor Types
July 7, 2026
 · 
4 min read
Press Releases
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
July 7, 2026
 · 
4 min read
Load More